Literature DB >> 8646555

Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region.

A Caputo1, M P Grossi, R Bozzini, C Rossi, M Betti, P C Marconi, G Barbanti-Brodano, P G Balboni.   

Abstract

Tat mutants (tat22, tat37 and tat22/37) were constructed in the transactivation domain, where cysteines at positions 22 or/and 37 were substituted with glycine and serine, respectively. These mutants were expressed either in a BK virus episomal vector or in the retroviral vector LXSN. Constitutive production of tat22 by Jurkat T cells in the context of both vectors blocked HIV-1 replication during lytic infection. Conversely, the tat37 mutant did not show any inhibitory activity and tat22/37 displayed a mild effect on HIV-1 infection only when expressed by the recombinant retrovirus. However, constitutive production of tat22/37 by the BK virus vector in Jurkat T cells chronically infected by HIV-1 was effective in blocking reactivation of viral replication induced by tumor necrosis factor-alpha or human herpesvirus-6. These results suggest that mutants in the transactivation domain of tat may be considered in designing alternative strategies to control HIV-1 replication and reactivation from latency during different phases of infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8646555

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

1.  The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat.

Authors:  K Fujinaga; T P Cujec; J Peng; J Garriga; D H Price; X Graña; B M Peterlin
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

2.  Novel pyridinium surfactants for efficient, nontoxic in vitro gene delivery.

Authors:  I van der Woude; A Wagenaar; A A Meekel; M B ter Beest; M H Ruiters; J B Engberts; D Hoekstra
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

3.  Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia.

Authors:  Daniel Cowley; Lachlan R Gray; Steven L Wesselingh; Paul R Gorry; Melissa J Churchill
Journal:  J Neurovirol       Date:  2010-11-30       Impact factor: 2.643

Review 4.  Anti-HIV ribozymes.

Authors:  L Q Sun; J A Ely; W Gerlach; G Symonds
Journal:  Mol Biotechnol       Date:  1997-06       Impact factor: 2.860

5.  Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency.

Authors:  Olaf Kutsch; Etty N Benveniste; George M Shaw; David N Levy
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Targeting tat inhibitors in the assembly of human immunodeficiency virus type 1 transcription complexes.

Authors:  Iván D'Orso; Jocelyn R Grunwell; Robert L Nakamura; Chandreyee Das; Alan D Frankel
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

7.  Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication.

Authors:  S F Ding; J Noronha; S Joshi
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

8.  Impact of Tat Genetic Variation on HIV-1 Disease.

Authors:  Luna Li; Satinder Dahiya; Sandhya Kortagere; Benjamas Aiamkitsumrit; David Cunningham; Vanessa Pirrone; Michael R Nonnemacher; Brian Wigdahl
Journal:  Adv Virol       Date:  2012-07-30

9.  Potent inhibition of HIV-1 replication by a Tat mutant.

Authors:  Luke W Meredith; Haran Sivakumaran; Lee Major; Andreas Suhrbier; David Harrich
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.